Viktoria Ekström-Rydén
Doktorand vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Gustav Ullenhag
- E-post:
- viktoria.ekstrom-ryden@igp.uu.se
- Besöksadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Publikationer
Senaste publikationer
-
Ingår i Nature Communications, 2026
- DOI för LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
- Ladda ner fulltext (pdf) av LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
-
Ingår i ESMO Open, 2026
- DOI för First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
- Ladda ner fulltext (pdf) av First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
-
Ingår i Biomarker Research, 2026
- DOI för Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
- Ladda ner fulltext (pdf) av Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
-
Ingår i Cancer Immunology and Immunotherapy, 2025
- DOI för Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Ladda ner fulltext (pdf) av Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
-
Ingår i Frontiers in Oncology, 2024
- DOI för Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Ladda ner fulltext (pdf) av Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
Alla publikationer
Artiklar i tidskrift
-
Ingår i Nature Communications, 2026
- DOI för LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
- Ladda ner fulltext (pdf) av LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
-
Ingår i ESMO Open, 2026
- DOI för First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
- Ladda ner fulltext (pdf) av First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
-
Ingår i Biomarker Research, 2026
- DOI för Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
- Ladda ner fulltext (pdf) av Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
-
Ingår i Cancer Immunology and Immunotherapy, 2025
- DOI för Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Ladda ner fulltext (pdf) av Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
-
Ingår i Frontiers in Oncology, 2024
- DOI för Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Ladda ner fulltext (pdf) av Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
-
Ingår i Pigment Cell & Melanoma Research, 2024
- DOI för The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Ladda ner fulltext (pdf) av The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
-
Ingår i Cancer Medicine, s. 13217-13224, 2023
- DOI för Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
- Ladda ner fulltext (pdf) av Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study